Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., de Marinis F., ...Daha Fazla

LANCET ONCOLOGY, cilt.19, sa.11, ss.1468-1479, 2018 (SCI-Expanded, Scopus) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 11
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/s1470-2045(18)30673-9
  • Dergi Adı: LANCET ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1468-1479
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.